Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations.
Marton KönigÅslaug Rudjord LorentzenHilde Marie TorgautenThe Trung TranStine Schikora-RustadEline Benno VaageÅse MyglandStig WergelandJan AarsethIngeborg Aase S AabergeØivind TorkildsenTrygve HolmøyTone BergeKjell-Morten MyhrHanne Flinstad HarboJan Terje AndersenLudvig Andre MuntheArne SøraasElisabeth Gulowsen CeliusJohn Torgils VaageFridtjof Lund-JohansenGro Owren NygaardPublished in: Journal of neurology, neurosurgery, and psychiatry (2021)
Patients treated with fingolimod or rituximab should be informed about the risk of reduced humoral immunity and vaccinations should be timed carefully in rituximab patients. Our results identify the need for studies regarding the durability of vaccine responses, the role of cellular immunity and revaccinations.
Keyphrases
- multiple sclerosis
- diffuse large b cell lymphoma
- sars cov
- immune response
- end stage renal disease
- chronic lymphocytic leukemia
- hodgkin lymphoma
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- low dose
- late onset
- respiratory syndrome coronavirus
- early onset
- binding protein
- amyotrophic lateral sclerosis